Outcome of Different Treatments of Overactive Bladder in Taiwan

What this Trial Is About

Overactive bladder (OAB) syndrome is a common condition that greatly affects patients' quality of life. This research aims to compare how three treatments—mirabegron, solifenacin, and botulinum neurotoxin type A (BoNTA)—influence bladder function, specifically looking at the mechanical work the bladder performs during urination using pressure-volume analysis (PVA). The study also explores the potential additional effects of BoNTA on bladder compliance through its impact on sympathetic nerve activity, providing deeper insight into bladder storage function. Participants will receive one of four treatments: oral solifenacin, oral mirabegron, a combination of solifenacin and mirabegron, or Botox injections. Each treatment group's bladder function will be assessed using urodynamic evaluations, including cystometry, conducted 1 month before and at 1 and 6 months after treatment. The study also includes a preclinical phase using a spinal cord injury rat model to examine these treatments' effects on bladder function in neurogenic detrusor overactivity, bridging clinical and animal research. Throughout the study, participants will undergo evaluations of bladder pressure and volume during voiding cycles, both before and several months after treatment, to measure changes in bladder work and compliance. These assessments will occur within voiding cycles lasting approximately 30 to 60 minutes. Researchers will closely monitor these outcomes to understand how each therapy affects bladder physiology. The total study period extends up to 12 months post-treatment, ensuring comprehensive follow-up and data collection.

Comparing Treatments for Overactive Bladder in Taiwan: A Study of Outcomes